- Motley Fool
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses.
- AASTOCKS
葛蘭素史克(GSK.US)向德國夥伴收購多款疫苗開發計劃控制權 共涉最多14.5億歐元
英國藥業巨擘葛蘭素史克(GSK)(GSK.US)周三(3日)宣布，與德國生物科技企業CureVac重建夥伴關係，將取得兩企聯合開發多款疫苗的控制權。 GSK將向CureVac支付4億歐元前期款額，並就開發/監管及銷售達至里程碑時支付額外最多10.5億歐元。 兩企自2020年起展開合作，利用信使核糖核酸技術(mRNA)開發多款傳染病疫苗。CureVac透過是次交易出售多項疫苗開發項目，取得前期款額，以提升現金水平及聚焦癌症治療。 GSK將會繼續開發新收購的臨床第二階段流感疫苗及新冠疫苗項目，以及處第一階段臨床或初步階段的禽流感疫苗項目。(da/a)~ 阿思達克財經新聞 網址: www.aastocks.com
- Bloomberg
Bird Flu Shot Hopes Dim as Tracing Woes Undercut Covid Lessons
(Bloomberg) -- US scientists haven’t gotten a handle on how to effectively track bird flu, three months after a Texas dairy worker was diagnosed with the virus. That’s impeding the ability to create a vaccine to protect against the spread among people.Most Read from BloombergDemocrats Weigh Mid-July Vote to Formally Tap Biden as NomineeTrump Immunity Ruling Means Any Trial Before Election UnlikelyBlackRock Buys Preqin for $3.2 Billion in Private Data PushTrump as President or Private Citizen: Wh
